Two multiple sclerosis cases developed herpes zoster during use of fingolimod

dc.authorscopusid23062131200
dc.authorscopusid8944423400
dc.authorscopusid56042671700
dc.authorscopusid57189598520
dc.authorscopusid58505968100
dc.contributor.authorTerzi, Murat
dc.contributor.authorDuman, Taşkın
dc.contributor.authorŞen, Sedat
dc.contributor.authorGüntel, Murat
dc.contributor.authorŞen, Nalan Örtücü
dc.date.accessioned2024-09-19T15:47:15Z
dc.date.available2024-09-19T15:47:15Z
dc.date.issued2018
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractMultiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system. Immunosuppressive and immunomodulating drugs are used during disease monitoring. Fingolimod is one of the immunomodulatory treatments used in MS patients. It is a therapeutic agent acting on lymphocytes. Latent varicella-zoster virus infections may occur in MS patients receiving fingolimod therapy. In this article, the information of two cases with varicella-zoster virus reactivation during fingolimod use were presented. © 2018 OMUen_US
dc.identifier.doi10.5835/jecm.omu.35.01.006
dc.identifier.endpage30en_US
dc.identifier.issn1309-4483
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85105278426en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage27en_US
dc.identifier.urihttps://doi.org/10.5835/jecm.omu.35.01.006
dc.identifier.urihttps://hdl.handle.net/20.500.12483/15069
dc.identifier.volume35en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherOndokuz Mayis Universitesien_US
dc.relation.ispartofJournal of Experimental and Clinical Medicine (Turkey)en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFingolimod Multiple sclerosis Varicella-zoster virus reactivation Zosteren_US
dc.titleTwo multiple sclerosis cases developed herpes zoster during use of fingolimoden_US
dc.typeArticleen_US

Dosyalar